BioLineRX
BLRX
28 hedge funds and large institutions have $1.47M invested in BioLineRX in 2024 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 5 closing their positions.
137% more capital inflows, than outflows
Capital inflows: $489K | Capital outflows: $207K
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
0.26% more ownership
Funds ownership: 1.54% → 1.8% (+0.26%)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
3% less funds holding
Funds holding: 29 → 28 (-1)
85% less call options, than puts
Call options by funds: $33K | Put options by funds: $223K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Values First Advisors
Gray,
Tennessee
|
+$190K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$94K |
| 3 |
Morgan Stanley
New York
|
+$66.6K |
| 4 |
XTX Topco
George Town,
Cayman Islands
|
+$39.5K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$29.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Virtu Financial
New York
|
-$48K |
| 2 |
JP Morgan Chase
New York
|
-$36.1K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$33.4K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$30.3K |
| 5 |
Allen Mooney & Barnes Investment Advisors
Thomasville,
Georgia
|
-$23.6K |
BLRX Hedge Fund Activity: Q1 2024 in Review
28 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2024, worth a combined $1.47M — down 16% from $1.75M a quarter earlier.
Fund positioning in BLRX was balanced in Q1 2024: 5 funds opened new positions, 5 closed out, 8 added to existing stakes and 6 trimmed.
The largest buyer was Values First Advisors, adding an estimated $190K. The largest seller was Virtu Financial, exiting entirely with an estimated $48K sold.
- 28 institutional investors held BioLineRX (BLRX) as of Q1 2024, down from 29 in Q4 2023.
- Funds reported $1.47M of BioLineRX stock for Q1 2024, down 16% quarter-over-quarter.
- 5 funds opened new BioLineRX positions in Q1 2024 and 5 closed out, a net change of 0 holders.
- The largest BioLineRX buyer in Q1 2024 was Values First Advisors, an estimated $190K added.
- The largest BioLineRX seller in Q1 2024 was Virtu Financial, an estimated $48K sold.
Based on aggregated 13F filings for Q1 2024.